donepezil has been researched along with Benign Neoplasms in 7 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness of donepezil compared with placebo in cancer patients with fatigue as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)." | 9.12 | Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. ( Bruera, E; Driver, LC; El Osta, B; Palmer, JL; Pei, BL; Poulter, VA; Shen, L; Valero, V, 2007) |
| "Donepezil 5 mg was given every morning for 7 days." | 6.71 | The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. ( Bruera, E; Burton, AW; Driver, LC; Palmer, JL; Shen, L; Strasser, F; Willey, J, 2003) |
| "To evaluate the effectiveness of donepezil compared with placebo in cancer patients with fatigue as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)." | 5.12 | Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. ( Bruera, E; Driver, LC; El Osta, B; Palmer, JL; Pei, BL; Poulter, VA; Shen, L; Valero, V, 2007) |
| "Donepezil 5 mg was given every morning for 7 days." | 2.71 | The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. ( Bruera, E; Burton, AW; Driver, LC; Palmer, JL; Shen, L; Strasser, F; Willey, J, 2003) |
| "Cognitive dysfunction is a challenging adverse effect of chemotherapy and radiotherapy that has limited treatment options." | 2.61 | Pharmacologic management of cognitive impairment induced by cancer therapy. ( Dietrich, J; Karschnia, P; Parsons, MW, 2019) |
| "Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck." | 2.50 | Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. ( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Sheng, K | 1 |
| Song, Y | 1 |
| Lei, F | 1 |
| Zhao, W | 1 |
| Fan, L | 1 |
| Wu, L | 1 |
| Liu, Y | 1 |
| Wu, S | 1 |
| Zhang, Y | 1 |
| Karschnia, P | 1 |
| Parsons, MW | 1 |
| Dietrich, J | 1 |
| Davis, J | 1 |
| Ahlberg, FM | 1 |
| Berk, M | 1 |
| Ashley, DM | 1 |
| Khasraw, M | 1 |
| Borghgraef, C | 1 |
| Libert, Y | 1 |
| Etienne, AM | 1 |
| Delvaux, N | 1 |
| Reynaert, C | 1 |
| Razavi, D | 1 |
| Castellino, SM | 1 |
| Ullrich, NJ | 1 |
| Whelen, MJ | 1 |
| Lange, BJ | 1 |
| Bruera, E | 2 |
| Strasser, F | 1 |
| Shen, L | 2 |
| Palmer, JL | 2 |
| Willey, J | 1 |
| Driver, LC | 2 |
| Burton, AW | 1 |
| El Osta, B | 1 |
| Valero, V | 1 |
| Pei, BL | 1 |
| Poulter, VA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719] | 200 participants (Anticipated) | Interventional | 2020-11-08 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for donepezil and Benign Neoplasms
| Article | Year |
|---|---|
Research progress in pharmacological activities and structure-activity relationships of tetralone scaffolds as pharmacophore and fluorescent skeleton.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Fluorescent Dyes; Humans; Molecular Structur | 2022 |
Pharmacologic management of cognitive impairment induced by cancer therapy.
Topics: Antineoplastic Agents; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognitive Dysfu | 2019 |
Emerging pharmacotherapy for cancer patients with cognitive dysfunction.
Topics: Antineoplastic Agents; Central Nervous System Stimulants; Cholinesterase Inhibitors; Clinical Trials | 2013 |
[Treatment of cognitive impairments in oncology: a review of longitudinal controlled studies].
Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Central Nervous System Stimulants; Cognition; Cog | 2014 |
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Attention; Benzhydryl Compounds; Br | 2014 |
2 trials available for donepezil and Benign Neoplasms
| Article | Year |
|---|---|
The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study.
Topics: Adult; Aged; Analgesics, Opioid; Donepezil; Female; Humans; Indans; Male; Middle Aged; Neoplasms; No | 2003 |
Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial.
Topics: Aged; Disease Progression; Donepezil; Double-Blind Method; Fatigue; Female; Humans; Indans; Male; Mi | 2007 |